NOROQUIN PRO-SALT

Indications

• African trypanosomiasis (sleeping sickness)
• Bovine trypanosomiasis
• Equine trypanosomiasis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing information. Doses may vary based on the condition being treated and the weight of the animal.

Mechanism of action

Quinapyramine exerts its pharmacological effects by inhibiting the activity of nucleic acid synthesis in trypanosomes, leading to cell death. Its action is thought to involve interference with mitochondrial function and the disruption of metabolic processes vital for the parasite's survival.

Pharmacodynamics

Quinapyramine demonstrates a selective toxicity towards trypanosomes, affecting their biochemical pathways while sparing host cells. The drug accumulates within the parasites, which enhances its effectiveness, especially in the presence of hypoxic conditions that further promote its uptake. The efficacy of quinapyramine is influenced by factors such as the stage of the disease and the specific trypanosome species involved.

Pharmacokinetics

Quinapyramine is well-absorbed after parenteral administration, with peak plasma concentrations occurring within hours. It has a moderate volume of distribution and is metabolized primarily in the liver. The elimination half-life varies based on the species treated and the route of administration, but it generally undergoes renal excretion. Careful monitoring of plasma levels may be necessary to avoid toxicity.

Pregnancy

There is limited information on the safety of quinapyramine in pregnancy. Caution is advised.

Breast-feeding

It is not known whether quinapyramine is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture.

Formulations

• {'formulation': 'Quinapyramine', 'type': 'Injection', 'strength': 'available in various strengths'}

Indications

• African sleeping sickness
• Trypanosomiasis in livestock

Dosage

Children: Refer to specific veterinary guidelines for dosing information, as it may vary based on species and infection severity.

Adults: Refer to specific veterinary guidelines for dosing information, as it may vary based on species and infection severity.

Mechanism of action

Quinapyramine acts by inhibiting the parasite's ability to synthesize DNA and RNA, ultimately leading to cell death. Its exact mechanism involves interference with the metabolism and energy production of Trypanosoma species, disrupting normal cellular processes.

Pharmacodynamics

The pharmacodynamics of quinapyramine involves its selective toxicity towards trypanosomes, allowing it to exert its therapeutic effects while minimizing harm to the host. It is effective against both the acute and chronic forms of trypanosomiasis, and its dosage may vary based on the severity of the infection and the specific strain of the parasite.

Pharmacokinetics

Quinapyramine is absorbed following administration and is distributed throughout the body. It undergoes metabolic processes in the liver and is excreted primarily via the kidneys. The pharmacokinetic profile may vary among different species, which is a consideration in veterinary applications.

Adverse effects

• Hypotension
• Dizziness
• Palpitations
• Headache
• Nausea
• Vomiting
• Diarrhea

Interactions

• May interact with antihypertensive medications, increasing the risk of hypotension
• Can enhance the effects of other anticholinergic drugs

Precautions

• Use with caution in patients with a history of cardiovascular disease
• Monitor blood pressure regularly
• Assess renal function before prescribing

Pregnancy

Quinapyramine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if quinapyramine is excreted in human milk, and caution should be exercised when administering to breastfeeding women.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.